Contact

All Stories

  1. Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease

    Article • The Journal of Prevention of Alzheimer s Disease, January 2026, Elsevier

    Dr. Raymond Scott Turner

  2. The financial consequences of undiagnosed memory disorders

    Article • Journal of Financial Economics, October 2025, Elsevier

    Dr. Raymond Scott Turner

  3. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease

    Article • International Journal of Molecular Sciences, May 2025, MDPI AG

    Dr. Raymond Scott Turner

  4. Aging as a target for the prevention and treatment of Alzheimer’s disease

    Article • Frontiers in Neurology, April 2024, Frontiers

    Dr. Raymond Scott Turner

  5. Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder

    Article • Neurology, January 2024, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  6. Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy

    Article • Journal of Neurochemistry, January 2024, Wiley

    Dr. Raymond Scott Turner

  7. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

    Article • Alzheimer s & Dementia, December 2023, Wiley

    Dr. Raymond Scott Turner

  8. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2023, New England Journal of Medicine (NEJM/MMS)

    Dr. Raymond Scott Turner

  9. The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort

    Article • Alzheimer s & Dementia, October 2023, Wiley

    Dr. Raymond Scott Turner

  10. Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort

    Article • Alzheimer s & Dementia, October 2023, Wiley

    Dr. Raymond Scott Turner

  11. An explainable machine learning model of cognitive decline derived from speech

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, October 2023, Wiley

    Dr. Raymond Scott Turner

  12. Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)

    Article • Alzheimer s & Dementia, September 2023, Wiley

    Dr. Raymond Scott Turner

  13. Influence of amyloid and diagnostic syndrome on non‐traditional memory scores in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, August 2023, Wiley

    Dr. Raymond Scott Turner

  14. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

    Article • Annals of Clinical and Translational Neurology, August 2023, Wiley

    Dr. Raymond Scott Turner

  15. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  16. Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  17. White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  18. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort

    Article • Alzheimer s & Dementia, June 2023, Wiley

    Dr. Raymond Scott Turner

  19. Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

    Article • Alzheimer s & Dementia, May 2023, Wiley

    Dr. Raymond Scott Turner

  20. Learning slopes in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, May 2023, Wiley

    Dr. Raymond Scott Turner

  21. Matrix disequilibrium in Alzheimer’s disease and conditions that increase Alzheimer’s disease risk

    Article • Frontiers in Neuroscience, May 2023, Frontiers

    Dr. Raymond Scott Turner

  22. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

    Article • Journal of Neuroinflammation, May 2023, Springer Science + Business Media

    Dr. Raymond Scott Turner

  23. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice

    Article • Neurobiology of Disease, April 2023, Elsevier

    Dr. Raymond Scott Turner

  24. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib induces autophagy and reduces inflammation and vascular fibrosis in Alzheimer’s disease

    Article • March 2023, Research Square

    Dr. Raymond Scott Turner

  25. Increasing access to cognitive screening in the elderly: Applying natural language processing methods to speech collected over the telephone

    Article • Cortex, November 2022, Elsevier

    Dr. Raymond Scott Turner

  26. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice

    Article • July 2022, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  27. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

    Article • Frontiers in Neurology, March 2022, Frontiers

    Dr. Raymond Scott Turner

  28. Corrigendum: A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease

    Article • Frontiers in Aging Neuroscience, March 2022, Frontiers

    Dr. Raymond Scott Turner

  29. Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV

    Article • AIDS Research and Human Retroviruses, March 2022, Mary Ann Liebert Inc

    Dr. Raymond Scott Turner

  30. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

    Article • Alzheimer s & Dementia Translational Research & Clinical Interventions, January 2022, Wiley

    Dr. Raymond Scott Turner

  31. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease

    Article • PLOS One, June 2021, PLOS

    Dr. Raymond Scott Turner

  32. Low CD4 nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV

    Article • AIDS, February 2021, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  33. Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout

    Article • Clinical Trials, January 2021, SAGE Publications

    Dr. Raymond Scott Turner

  34. Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer’s Disease

    Article • Aging and Disease, January 2021, Aging and Disease

    Dr. Raymond Scott Turner

  35. Acceptability of collecting speech samples from the elderly via the telephone

    Article • Digital Health, January 2021, SAGE Publications

    Dr. Raymond Scott Turner

  36. A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease

    Article • Frontiers in Aging Neuroscience, December 2020, Frontiers

    Dr. Raymond Scott Turner

  37. Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias

    Article • Frontiers in Neurology, June 2020, Frontiers

    Dr. Raymond Scott Turner

  38. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease

    Article • Annals of Neurology, May 2020, Wiley

    Dr. Raymond Scott Turner

  39. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  40. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

    Article • JAMA Neurology, October 2019, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  41. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study

    Article • Journal of Clinical Oncology, November 2018, American Society of Clinical Oncology (ASCO)

    Dr. Raymond Scott Turner

  42. Does treatment with resveratrol improve outcomes in patients with Alzheimer's disease?

    Article • Annals of the New York Academy of Sciences, August 2017, Wiley

    Dr. Raymond Scott Turner

  43. Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing

    Article • Neuropharmacology, May 2017, Elsevier

    Dr. Raymond Scott Turner

  44. Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease

    Article • Neurobiology of Aging, March 2017, Elsevier

    Dr. Raymond Scott Turner

  45. 11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease

    Article • Neurology, February 2017, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  46. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

    Article • Journal of Neuroinflammation, January 2017, Springer Science + Business Media

    Dr. Raymond Scott Turner

  47. The BIOCARD Index

    Article • Alzheimer Disease & Associated Disorders, January 2017, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  48. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease

    Article • Neurobiology of Aging, August 2016, Elsevier

    Dr. Raymond Scott Turner

  49. Hexa (ethylene glycol) derivative of benzothiazole aniline promotes dendritic spine formation through the RasGRF1–Ras dependent pathway

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, February 2016, Elsevier

    Dr. Raymond Scott Turner

  50. An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, January 2016, Wiley

    Dr. Raymond Scott Turner

  51. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

    Article • Neurology, September 2015, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  52. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models

    Article • Neuroscience, September 2015, Elsevier

    Dr. Raymond Scott Turner

  53. Corrigendum to “A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease” [Exp. Neurol. 252 (2014) 105–113]

    Article • Experimental Neurology, November 2014, Elsevier

    Dr. Raymond Scott Turner

  54. Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?

    Article • Journal of Clinical Oncology, June 2014, American Society of Clinical Oncology (ASCO)

    Dr. Raymond Scott Turner

  55. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease

    Article • Experimental Neurology, February 2014, Elsevier

    Dr. Raymond Scott Turner

  56. Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know?

    Article • Seminars in Oncology, December 2013, Elsevier

    Dr. Raymond Scott Turner

  57. Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking

    Article • Biochemical and Biophysical Research Communications, October 2013, Elsevier

    Dr. Raymond Scott Turner

  58. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease

    Article • Brain, June 2013, Oxford University Press (OUP)

    Dr. Raymond Scott Turner

  59. A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis

    Article • Journal of Neuroscience, May 2013, Society for Neuroscience

    Dr. Raymond Scott Turner

  60. Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions

    Article • Neurocase, February 2013, Taylor & Francis

    Dr. Raymond Scott Turner

  61. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

    Article • Experimental Neurology, January 2013, Elsevier

    Dr. Raymond Scott Turner

  62. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease

    Article • Journal of Neurochemistry, November 2012, Wiley

    Dr. Raymond Scott Turner

  63. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study

    Article • Neurobiology of Aging, December 2011, Elsevier

    Dr. Raymond Scott Turner

  64. Age-related loss of noradrenergic neurons in the brains of triple transgenic mice

    Article • AGE, November 2011, Springer Science + Business Media

    Dr. Raymond Scott Turner

  65. Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice

    Article • Brain Research, September 2011, Elsevier

    Dr. Raymond Scott Turner

  66. Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors

    Article • Archives of Neurology, March 2011, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  67. ApoE Receptor 2 Regulates Synapse and Dendritic Spine Formation

    Article • PLOS One, February 2011, PLOS

    Dr. Raymond Scott Turner

  68. Validation of Consensus Panel Diagnosis in Dementia

    Article • Archives of Neurology, December 2010, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  69. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines

    Article • Neuroscience, August 2010, Elsevier

    Dr. Raymond Scott Turner

  70. ApoE mimetic peptide decreases Aβ production in vitro and in vivo

    Article • Molecular Neurodegeneration, January 2010, Springer Science + Business Media

    Dr. Raymond Scott Turner

  71. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease

    Article • Journal of Neuroinflammation, January 2010, Springer Science + Business Media

    Dr. Raymond Scott Turner

  72. ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo

    Article • Journal of Neuroscience, December 2009, Society for Neuroscience

    Dr. Raymond Scott Turner

  73. X11α haploinsufficiency enhances Aβ amyloid deposition in Alzheimer's disease transgenic mice

    Article • Neurobiology of Disease, October 2009, Elsevier

    Dr. Raymond Scott Turner

  74. The cytoplasmic adaptor protein X11  and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement

    Article • The FASEB Journal, August 2009, Federation of American Societies For Experimental Biology (FASEB)

    Dr. Raymond Scott Turner

  75. Amyloid-β-Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving a Controversy

    Article • Neurotoxicity Research, March 2009, Springer Science + Business Media

    Dr. Raymond Scott Turner

  76. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

    Article • Brain, October 2007, Oxford University Press (OUP)

    Dr. Raymond Scott Turner

  77. Alzheimer's Disease

    Article • Seminars in Neurology, November 2006, Thieme Publishing Group

    Dr. Raymond Scott Turner

  78. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?

    Article • Experimental Neurology, February 2004, Elsevier

    Dr. Raymond Scott Turner

  79. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging

    Article • Statistics in Medicine, January 2004, Wiley

    Dr. Raymond Scott Turner

  80. Biomarkers of alzheimer’s disease and mild cognitive impairment: are we there yet?

    Article • Experimental Neurology, September 2003, Elsevier

    Dr. Raymond Scott Turner

  81. X11α modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the yenpty sequence

    Article • Neuroscience, August 2003, Elsevier

    Dr. Raymond Scott Turner

  82. Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease

    Article • Learning & Memory, September 2002, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  83. Inherited dementias

    Article • Neurologic Clinics, August 2002, Elsevier

    Dr. Raymond Scott Turner

  84. Synergistic Effects of Munc18a and X11 Proteins on Amyloid Precursor Protein Metabolism

    Article • Journal of Biological Chemistry, May 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  85. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways

    Article • Journal of Neurochemistry, March 2002, Wiley

    Dr. Raymond Scott Turner

  86. Differentiated Human NT2-N Neurons Possess a High Intracellular Content of myo-Inositol

    Article • Journal of Neurochemistry, December 2001, Wiley

    Dr. Raymond Scott Turner

  87. The Protease Inhibitor, MG132, Blocks Maturation of the Amyloid Precursor Protein Swedish Mutant Preventing Cleavage by β-Secretase

    Article • Journal of Biological Chemistry, November 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  88. Modulation of Amyloid Precursor Protein Metabolism by X11α/Mint-1

    Article • Journal of Biological Chemistry, September 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  89. FORUM What Persian Gulf War Syndrome?

    Article • The Clinical Neuropsychologist, August 2000, Taylor & Francis

    Dr. Raymond Scott Turner

  90. Identification of an Evolutionarily Conserved Heterotrimeric Protein Complex Involved in Protein Targeting

    Article • Journal of Biological Chemistry, November 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  91. The Chaperone BiP/GRP78 Binds to Amyloid Precursor Protein and Decreases Aβ40 and Aβ42 Secretion

    Article • Journal of Biological Chemistry, October 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  92. X11 Interaction with β-Amyloid Precursor Protein Modulates Its Cellular Stabilization and Reduces Amyloid β-Protein Secretion

    Article • Journal of Biological Chemistry, August 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  93. The X11α Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces Aβ40 and Aβ42 Secretion

    Article • Journal of Biological Chemistry, June 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  94. Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons

    Article • The Journal of Comparative Neurology, October 1996, Wiley

    Dr. Raymond Scott Turner

  95. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia

    Article • Annals of Neurology, February 1996, Wiley

    Dr. Raymond Scott Turner

  96. Phospholipid/calcium-dependent protein kinase (protein kinase C) system: A major site of bioregulation

    Article • Advances in Enzyme Regulation, January 1986, Elsevier

    Dr. Raymond Scott Turner

  97. Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C)

    Article • Biochemical and Biophysical Research Communications, January 1986, Elsevier

    Dr. Raymond Scott Turner

  98. Phospholipid-Sensitive Ca2+-Dependent Protein Kinase Preferentially Phosphorylates Serine-115 of Bovine Myelin Basic Protein

    Article • Journal of Neurochemistry, November 1984, Wiley

    Dr. Raymond Scott Turner

  99. Developmental studies of phospholipid-sensitive Ca2+-dependent protein kinase and its substrates and of phosphoprotein phosphatases in rat brain.

    Article • Proceedings of the National Academy of Sciences, May 1984, Proceedings of the National Academy of Sciences

    Dr. Raymond Scott Turner

  100. Phospholipid-sensitive Ca2+-dependent protein kinase: a major protein phosphorylation system

    Article • Molecular and Cellular Endocrinology, May 1984, Elsevier

    Dr. Raymond Scott Turner

  101. S-100 and Other Acidic Proteins Promote Ca2+-Independent Phosphorylation of Protamine Catalyzed by a New Protein Kinase from Brain

    Article • Journal of Neurochemistry, February 1984, Wiley

    Dr. Raymond Scott Turner

  102. Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, A calmodulin antagonist

    Article • Biochemical Pharmacology, January 1984, Elsevier

    Dr. Raymond Scott Turner

  103. Comparative abilities of lanthanide ions La3+ and Tb3+ to substitute for Ca2+ in regulating phospholipid-sensitive Ca2+-dependent protein kinase and myosin light chain kinase

    Article • Life Sciences, July 1983, Elsevier

    Dr. Raymond Scott Turner

  104. Cobra polypeptide cytotoxin I and marine worm polypeptide cytotoxin A-IV are potent and selective inhibitors of phospholipid-sensitive Ca2+ -dependent protein kinase

    Article • FEBS Letters, March 1983, Wiley

    Dr. Raymond Scott Turner

  105. Basic Protein in Brain Myelin Is Phosphorylated by Endogenous Phospholipid-Sensitive Ca2+-Dependent Protein Kinase

    Article • Journal of Neurochemistry, November 1982, Wiley

    Dr. Raymond Scott Turner

  106. Methionine-enkephalin and morphine: Amount ejected microiontophoretically

    Article • Journal of Neuroscience Methods, August 1981, Elsevier

    Dr. Raymond Scott Turner